The Versamune® nano-platform is based on synthetic positively-charged lipids. The proprietary technology is protected by several patents.

The technology works when administered together with a disease or cancer-specific antigen to prime and target a T-cell response specifically against cells displaying the particular antigen,  Treatment with the Versamune-based immunotherapies result in a stimulation of both the innate and adaptive arms of the immune system. Preclinical studies also suggest significant reduction in the tumors defense mechanisms leading to powerful anti-tumor efficacy.

The versamune platform is built on critical components of cancer immunotherapy that have been demonstrated in the field of tumor immunology and various clinical studies to be clinically important.

PDS Biotechnology illustration